跳至主要内容

Build a new drug empowerment ecosystem, Medicilon Academician Innovative Drug Maturation Center - New Drug Ecological Assistance Platform Press Conference was successfully completed

 On November 30, the "Focus on the development of innovative drugs and promote the upgrading of the industrial chain - Medicilon Academician Innovative Drug Maturation Center - New Drug Ecological Assistance Platform Press Conference" hosted by Shanghai Medicilon Inc. (Medicilon) was grandly held.  More than 100 expert representatives from the government, industry, academia, and financial industry jointly witnessed a brand-new new drug empowering ecosystem, the technology empowerment platform of the Medicilon Academician Innovative Drug Maturation Center, the front-end new drug investment and financing support platform and the back-end new drug R&D trading platform ecological chains.

Academician Project Settlement Signing
Medicilon helps more scientific research results blooming 


 Academician Project Settlement Signing.webp

Academician Project Settlement Signing

At the signing ceremony, Professor Shuangqing Peng, Chief Scientific Officer of Medicilon, and Dr. Jian Liu, President of the Drug Discovery Division, signed the contract with Guoqiang Lin and Academician Li Jia on behalf of Medicilon.

Taking this signing as an opportunity, the two parties will have in-depth linkage and sincere collaboration, accelerate the implementation of collaboration projects, and achieve complementary advantages, mutual benefit, win-win, and common development.

Medicilon Academician Innovative Drug Maturation Center - New Drug Ecological Assistance Platform 
Born to build a new drug R&D ecosystem


Medicilon Academician Innovative Drug Maturation Center - New Drug Ecological Assistance Platform Officially Released.webpMedicilon Academician Innovative Drug Maturation Center - New Drug Ecological Assistance Platform Officially Released

Under the attention of the whole audience, Academician Li Jia, Deputy Director of Zhangjiang Administration Bureau Jun Wu, and Medicilon Chairman Jinzhang Chen took the stage to water the ecological tree together.  This means that all parties will work together to promote the ecological construction of the biomedical industry and work together to water it into a towering tree with lush branches and leaves.

Medicilon Empowering Ecosystem - New Drug Investment and Financing Assistance Platform
Aims to provide financial support for new drug research and development


Medicilon's empowering ecology and new drug investment and financing support platform aims to provide financial support for new drug research and development.  Medicilon has cooperated with a number of financial institutions to create a new investment and financing support platform to provide stable financial support for all aspects of new drug research and development, testing, and launch.

Investment and Financing Assistance Consultant Recruitment Ceremony.webpInvestment and Financing Assistance Consultant Recruitment Ceremony

Next, Dr. Jinzhang Chen and Dr. Chunlin Chen took the stage and awarded employment certificates to Ling Cen, Founding Director of Fudan University School of Management, Zhenhua Zheng, Managing Partner of Shenzhen Triwise International Capital Management, Ronggang Xie, Partner of Loyal Valley Capital, and other investment and financing consultants.  We look forward to them providing valuable suggestions and support for the development of Medicilon’s empowering ecosystem and new drug investment and financing platform in the future.

Medicilon Empowers Ecosystem - New Drug R&D Trading Platform
Facilitate the transformation and trading of phased results of new drug research and development


The new drug investment and financing assistance and empowerment platform aims to provide financial support for new drug research and development, while the new drug research and development trading platform facilitates the transformation and trading of new drug research and development stage results by establishing an open and transparent platform.  At the same time, it also encourages more scientific researchers to invest in the research and development of new drugs, helping scientific research results to be better displayed and rewarded.

Dr. Xianlian Wang, Head of Scientific Research of Medicilon Pharmalego® Platform.webpDr. Xianlian Wang, Head of Scientific Research of Medicilon Pharmalego® Platform

In order to meet the market demand for high-end intermediates, Medicilon has established an e-commerce platform for pharmaceutical intermediates - Pharmalego (cn.pharmalego.com).  Dr. Xianlian Wang, Head of Scientific Research of Medicilon's Pharmalego® platform, introduced that Pharmalego integrates the production, sales and customized synthesis services of high-end pharmaceutical intermediates.  Its core products include PROTAC® Building Blocks, nucleotides, ADC linkers, delivery systems, etc. , which can provide products from technical level, research level, reference standard level.

Whatever you do with accumulated strength, you will be victorious in everything you do; whatever you do with wisdom, you will be successful in everything.  The Medicilon Academician Innovative Drug Maturation Center - New Drug Ecological Assistance Platform has since embarked on a new journey, which is also an expedition full of missions and dreams.  Facing the future, Medicilon will firmly grasp the requirements of the times for unity and struggle, adhere to integrity and innovation.  Relying on Medicilon's empowering ecology and new drug investment and financing support platform, one-stop biomedical preclinical R&D service platform, and new drug R&D and trading platform ecosystem, multiple measures are taken to help the transformation of scientific and technological achievements and help achieve the goal of "Healthy China 2030"!

评论

发表评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...
发表评论
阅读全文

What is Toxicokinetics?

Toxicokinetics  is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms  toxicokinetics ,  pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...
发表评论
阅读全文